Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

What's fueling the biotech engine?

Nature Biotechnology volume 25, pages 1097–1104 (2007)Cite this article

A survey of market trends for biotech products shows that only a handful out of more than one hundred biologics have been fueling the double-digit rise in revenues in the sector.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2: Top ten categories of biologic drugs in terms of US sales in 2006.
Figure 3: Top 18 companies that comprised the majority of sales of biologic drugs in 2006.
Figure 4: Trends in US sales of recombinant growth factors.
Figure 5: Trends in US sales of mAbs.
Figure 6: Trends in US sales of recombinant hormones.
Figure 7: US sales of recombinant cytokines and blood factors ($ billions).
Figure 8: US sales of recombinant enzymes, recombinant vaccines and nucleic acid therapeutics ($ billions).

References

  1. Miller, H.I. As biotech turns 20. Nat. Rev. Drug Discov. 1, 1007–1008 (2002).

    Article  CAS  Google Scholar 

  2. Walsh, G. Biopharmaceutical benchmarks 2006. Nat. Biotechnol. 24, 769–776 (2006).

    Article  CAS  Google Scholar 

  3. Remuzzi, G. & Ingelfinger, J.R. Correction of anemia–payoffs and problems. N. Engl. J. Med. 355, 2144–2146 (2006).

    Article  CAS  Google Scholar 

  4. Khuri, F.R. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N. Engl. J. Med. 356, 2445–2448 (2007).

    Article  CAS  Google Scholar 

  5. Dooren, J.C. Medicare may limit anemia drug money: payment eligibility would be narrowed; Amgen J&J Impact. Wall Street Journal D.2 (May 15, 2007).

  6. Chase, M. A victory for anemia patients? Advocates beat back efforts to limit use of the popular drugs that carry heart risks. Wall Street Journal D.1 (July 31, 2007)

  7. Senior, M. Why EPO matters. In Vivo, 18–24 (July/August 2006).

  8. Reichert, J.M. & Valge-Archer, V.E. Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 6, 349–356 (2007).

    Article  CAS  Google Scholar 

  9. Reichert, J. & Pavolu, A. Monoclonal antibodies market. Nat. Rev. Drug Discov. 3, 383–384 (2004).

    Article  CAS  Google Scholar 

  10. Mount, C. & Featherstone, J. Rheumatoid arthritis market. Nat. Rev. Drug Discov. 4, 11–12 (2005).

    Article  CAS  Google Scholar 

  11. Bain, B. & Brazil, M. Adalimumab. Nat. Rev. Drug Discov. 2, 693–694 (2003).

    Article  CAS  Google Scholar 

  12. Michels, S., Rosenfeld, P.J., Puliafito, C.A., Marcus, E.N. & Venkatraman, A.S. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112, 1035–1047 (2005).

    Article  Google Scholar 

  13. Steinbrook, R. The price of sight–ranibizumab, bevacizumab, and the treatment of macular degeneration. N. Engl. J. Med. 355, 1409–1412 (2006).

    Article  CAS  Google Scholar 

  14. Hirsch, I.B. Insulin analogues. N. Engl. J. Med. 352, 174–183 (2005).

    Article  CAS  Google Scholar 

  15. Arlene, W. From Pfizer, Irrational Exubera? Bus. Week, p. 32 (July 16, 2006).

  16. Rother, K.I. Diabetes treatment–bridging the divide. N. Engl. J. Med. 356, 1499–1501 (2007).

    Article  CAS  Google Scholar 

  17. Davidson, S. Biogen, Serono squabble over MS market. Nat. Biotechnol. 19, 696–697 (2001).

    Article  CAS  Google Scholar 

  18. Dzik, W.H. Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII. J. Intensive Care Med. 21, 54–59 (2001).

    Article  Google Scholar 

  19. Anand, G. Why Genzyme can charge so much for Cerezyme. Wall St. J. (East Ed.), A15 (November 16, 2005).

  20. Abbott, A. Lyme disease: uphill struggle. Nature 439, 524–525 (2006).

    Article  CAS  Google Scholar 

  21. Glass, R.I., Bresee, J.S., Parashar, U.D., Jiang, B. & Gentsch, J. The future of rotavirus vaccines: a major setback leads to new opportunities. Lancet 363, 1547–1550 (2004).

    Article  Google Scholar 

  22. Thomas, M.B. Lilly's Xigris drug to treat infection had FDA approval. Wall Street Journal B.5 (Nov. 23, 2001).

  23. Schrag, D. The price tag on progress–chemotherapy for colorectal cancer. N. Engl. J. Med. 351, 317–319 (2004).

    Article  CAS  Google Scholar 

  24. Opal, S.M. Can we resolve the treatment of sepsis? Lancet 369, 803–804 (2007).

    Article  Google Scholar 

  25. Booth, B.L. & Zemmel, R.W. The search for blockbuster drugs. The McKinsey Quarterly (August 2004). Web exclusive http://www.mckinseyquarterly.com/ The_search_for_blockbuster_drugs_1474_abstract

    Google Scholar 

  26. Cohen, R.G. Entry order as consideration of follow-on biologics. N. Eng. J. Med. 357, 841–843 (2007).

    Article  Google Scholar 

  27. Frank, R.G. Regulation of follow-on biologics. N. Engl. J. Med. 357, 841–843 (2007).

    Article  CAS  Google Scholar 

  28. Woodcock, J. et al. The FDA's assessment of follow-on protein products: a historical perspective. Nat. Rev. Drug Discov. 6, 437–442 (2007).

    Article  Google Scholar 

Download references

Acknowledgements

S.A. thanks the affiliated institutions for access to journals and news articles. S.A. also thanks Ozlem Topaloglu (Johns Hopkins), Samuel R. Denmeade (Johns Hopkins), Kevin Fitzpatrick (IMS Health), Nitin Patel (IMS Health) and Chris Francis (IMS Health) for insightful discussions. This manuscript was submitted to Nature Biotechnology in June, 2007.

Author information

Authors and Affiliations

  1. Saurabh Aggarwal is a healthcare consultant based in New York. saurabhaggarwal@gmail.com,

    Saurabh Aggarwal

Authors
  1. Saurabh Aggarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aggarwal, S. What's fueling the biotech engine?. Nat Biotechnol 25, 1097–1104 (2007). https://doi.org/10.1038/nbt1007-1097

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1007-1097

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing